article thumbnail

Does the Drug Shortage White Paper Fall Short?

The FDA Law Blog

The White Paper notes that of the 123 drugs in shortage in January 2024, a quarter were first reported in shortage prior to 2020, with the oldest dating back to 2012, and shortages were experienced across therapeutic areas; analgesics/anesthetics (17%), anti-infective (12%), and cardiovascular (13%) products comprised 42% of shortages.

FDA 59
article thumbnail

Where can I get phentermine?

The Checkup by Singlecare

RELATED: Overweight and obesity statistics 2024 Where can I get phentermine? Since phentermine is a controlled substance, you need to be cautious and ensure that you are purchasing from a reputable and licensed online pharmacy if you have to.” Where can I get phentermine pills?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Strattera vs Vyvanse: Differences, Similarities, and Which One is Better For You

The Checkup by Singlecare

Capsule Capsule or chewable tablet What is the standard adult dosage? The FDA’s drug shortage database cites all generic manufacturers of lisdexamfetamine as having limited to no product availability as of April 2024. For these reasons, Vyvanse is considered a controlled substance by the Drug Enforcement Administration (DEA).

article thumbnail

Joint Basis for FDA/HHS Marijuana Rescheduling Recommendation Unveiled

The FDA Law Blog

Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. HHS forwards FDA’s analysis and recommendation to DEA.

FDA 69
article thumbnail

DEA Concurs: Marijuana Meets Schedule III Criteria

The FDA Law Blog

Houck — The Associated Press reported on Tuesday following confirmation by five anonymous individuals with knowledge that the Drug Enforcement Administration (“DEA”) is moving to reschedule marijuana from schedule I to the less stringently controlled schedule III. treaty obligations in rescheduling. 21 U.S.C. § 812(b)(1).